Glioma Treatment

Glioma Treatment

Global Glioma Treatment Market to Reach US$8.3 Billion by 2030

The global market for Glioma Treatment estimated at US$4.9 Billion in the year 2023, is expected to reach US$8.3 Billion by 2030, growing at a CAGR of 8.0% over the analysis period 2023-2030. Surgery, one of the segments analyzed in the report, is expected to record a 6.8% CAGR and reach US$2.9 Billion by the end of the analysis period. Growth in the Chemotherapy segment is estimated at 7.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.3 Billion While China is Forecast to Grow at 7.7% CAGR

The Glioma Treatment market in the U.S. is estimated at US$1.3 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.3 Billion by the year 2030 trailing a CAGR of 7.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.1% and 6.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.5% CAGR.

Global Glioma Treatment Market - Key Trends and Drivers Summarized

Gliomas are a diverse group of brain tumors originating from glial cells, which support and protect neurons in the central nervous system. Treatment of gliomas varies significantly based on the tumor`s grade, location, and genetic characteristics. High-grade gliomas, such as glioblastomas, are particularly aggressive and challenging to treat, necessitating a multimodal approach that typically includes surgery, radiation therapy, and chemotherapy. Temozolomide, an oral chemotherapy drug, is commonly used in combination with radiotherapy due to its ability to penetrate the blood-brain barrier and improve patient outcomes. Recent advancements in molecular profiling have led to more personalized treatment strategies, with targeted therapies and immunotherapies offering new hope for patients with specific genetic mutations.

Innovative treatments for glioma are being driven by breakthroughs in biotechnology and a deeper understanding of tumor biology. Precision medicine approaches, which tailor treatments based on an individual’s genetic makeup, are increasingly employed to enhance efficacy and minimize side effects. For instance, therapies targeting specific mutations such as IDH1/2 inhibitors and EGFR inhibitors are under active investigation in clinical trials. Additionally, immunotherapy, including checkpoint inhibitors and CAR-T cell therapy, has shown promise in harnessing the body’s immune system to combat glioma cells. Advances in drug delivery systems, such as convection-enhanced delivery and nanoparticle-based carriers, are also improving the targeted delivery of chemotherapeutic agents, thereby increasing their concentration at the tumor site while reducing systemic toxicity.

The growth in the glioma treatment market is driven by several factors. Key among these is the increasing incidence of gliomas and the significant unmet medical need for effective therapies. Technological advancements in molecular diagnostics have enabled the identification of actionable genetic mutations, driving the adoption of targeted therapies. The expanding field of immunotherapy and its success in other cancer types have spurred investment in glioma-specific immune-based treatments. Additionally, the development of novel drug delivery mechanisms has expanded the therapeutic landscape by improving the precision and efficacy of existing treatments. Government and private sector funding for brain cancer research, along with regulatory incentives such as orphan drug designations, further propel market growth. Moreover, growing awareness of glioma symptoms and advancements in imaging technologies contribute to earlier diagnosis and intervention, improving treatment outcomes and driving demand for advanced therapies. Collectively, these factors are fostering a dynamic and rapidly evolving market for glioma treatments.

Select Competitors (Total 86 Featured) -

• Amgen Inc.
• Amneal Pharmaceuticals, LLC
• Ariceum Therapeutics GmbH
• Azurity Pharmaceuticals, Inc. (Gliade)
• Bristol-Myers Squibb Company
• CNS Therapeutics, Inc.
• Denovo Biopharma LLC
• Elekta
• F. Hoffmann-La Roche Ltd.,
• ITM Isotope Technologies Munich SE
• Karyopharm Therapeutics, Inc.
• Lantern Pharma Inc.
• Novartis AG
• Novocure
• VBI Vaccines Inc.;

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.